|
|
Post by newmnkdinvestor on Jul 1, 2015 17:27:55 GMT -5
Seniors read magazine ads. Young people go on social media. Targeting young people in magazines would be a waste of money. So there is not one magazine geared towards younger people? Responding and reading are two entirely different things. |
|
|
|
Post by dreamboatcruise on Jul 1, 2015 17:56:07 GMT -5
Seniors read magazine ads. Young people go on social media. Targeting young people in magazines would be a waste of money. So there is not one magazine geared towards younger people? Responding and reading are two entirely different things. Media targeting people with T1 would seem to skew younger. If they get targeted like that I could see an ad portraying an active young person. |
|
|
|
Post by lynn on Jul 1, 2015 20:33:24 GMT -5
Lynn said circle jerk. Sorry but i just can't stop laughing about this.  Oops , I honestly didn't know what that meant , it just popped into my train of thought yesterday & I now realize I meant KNEE jerk reaction ! I just googled the other word and it made me blush bright red ./ note to self : don't ever post a knee jerk reaction after a 12 hour shift as the wrong word might end up being used instead , OMG ! I'm just glad that I am able to laugh at myself ! AND that I could still Edit  |
|
|
|
Post by robsacher on Jul 2, 2015 8:23:46 GMT -5
|
|
|
|
Post by robsacher on Jul 2, 2015 8:30:16 GMT -5
newmnkdinvestor, I am sure Sanofi will promote Afrezza to many different potential user groups but starting with seniors is a very good idea since seniors make up the largest portion of the T2 diabetic community. They account for over 25% of all diabetics and they are very poorly administered with injection insulin therapy. Doctors allow them to remain with unhealthy A1C levels over 8 before starting night time injection. But, with Afrezza, the elderly can start with a meal time insulin, Afrezza, which will help to lower their A1C, without the same level of hypoglycemic risk associated with injections. Please take a look at an article I wrote on the subject. It should answer some of your questions: seekingalpha.com/article/3201286-mannkinds-afrezza-inhaled-insulin-a-game-changer-for-seniors-with-diabetes?auth_param=2hisp:1alqr2c:77d42ea8b2b1f626a13cdc0fb5447fa6&uprof=44Best wishes, RS |
|
|
|
Post by robsacher on Jul 2, 2015 8:39:38 GMT -5
lynn,
For your information, the person writing here as "abovemyraising" is likely a well known basher who also is called Bear Crusher, Looking For Diogenes, and a few other names at SA forums.
Best wishes,
RS
|
|
|
|
Post by compound26 on Jul 2, 2015 8:39:42 GMT -5
newmnkdinvestor, I am sure Sanofi will promote Afrezza to many different potential user groups but starting with seniors is a very good idea since seniors make up the largest portion of the T2 diabetic community. They account for over 25% of all diabetics and they are very poorly administered with injection insulin therapy. Doctors allow them to remain with unhealthy A1C levels over 8 before starting night time injection. But, with Afrezza, the elderly can start with a meal time insulin, Afrezza, which will help to lower their A1C, without the same level of hypoglycemic risk associated with injections. Please take a look at an article I wrote on the subject. It should answer some of your questions: seekingalpha.com/article/3201286-mannkinds-afrezza-inhaled-insulin-a-game-changer-for-seniors-with-diabetes?auth_param=2hisp:1alqr2c:77d42ea8b2b1f626a13cdc0fb5447fa6&uprof=44Best wishes, RS Agree. Here is what the author of "The Failure of Exubera: Are We Beating a Dead Horse?" has to say about this issue: www.ncbi.nlm.nih.gov/pmc/articles/PMC2769732/As mentioned before, elderly patients might also represent a huge group of patients that are interested in an easy-to-use inhaler that requires no dialing of the insulin dose on an insulin pen or complex handling of an inhaler. For many of these patients, optimal metabolic control is the therapeutic target but application of at least some insulin with each meal would help keep their postprandial glycemic excursions in an acceptable range. We should also not ignore the fact that in many countries of the world beside the United States and Europe selfadministration of a substance/drug is disliked by patients because of cultural/religious reasons. For such patients, and their number is increasing rapidly, the possibility of inhaling a drug is a very attractive option. It might very well be that the big pharmaceutical companies of the western hemisphere, which are very much focused on the classical markets, will be surprised by the rapidity and consequence with which pharmaceutical companies in China or India will come along with developments specifically developed for their own countries, which do represent huge markets. |
|
|
|
Post by newmnkdinvestor on Jul 2, 2015 9:07:09 GMT -5
I have no issues about who they are targeting. I realize type 2 seniors is one of the biggest markets out there. I have an issue with that ad and the thought put into it. My wife is a marketing manager for a fortune 500 company. I sell reverse mortgage and have 10 years of marketing experience to seniors. We printed the ad and discussed it at dinner. The ad is poorly thought out. From the description of the inhaler to the person they use. Most seniors are not going to relate to a hip well dressed user (especially when most diabetics are in the south) who looks like he is getting ready to smoke a joint.
|
|
|
|
Post by BD on Jul 2, 2015 9:42:57 GMT -5
lynn, For your information, the person writing here as "abovemyraising" is likely a well known basher who also is called Bear Crusher, Looking For Diogenes, and a few other names at SA forums. Best wishes, RS Make that "who used to write"  |
|
|
|
Post by harryx1 on Jul 2, 2015 10:01:59 GMT -5
|
|
|
|
Post by novafett on Jul 2, 2015 10:36:46 GMT -5
Lynn said circle jerk. Sorry but i just can't stop laughing about this. Oops , I honestly didn't know what that meant , it just popped into my train of thought yesterday & I now realize I meant KNEE jerk reaction ! I just googled the other word and it made me blush bright red ./ note to self : don't ever post a knee jerk reaction after a 12 hour shift as the wrong word might end up being used instead , OMG ! I'm just glad that I am able to laugh at myself ! AND that I could still Edit Haha, yea i have to say i did wonder if you knew what the word really meant. You using that term didn't sync with the picture i have of you in my head. Good for a chuckle anyway, especially the post blushing part. |
|
|
|
Post by newmnkdinvestor on Jul 2, 2015 10:56:04 GMT -5
That's a solid picture to use. Simple, genuine smile, not dressed like she lives in NYC. I am from NYC btw.
She has worked hard in promoting afrezza to other diabetics so its nice to see she is going to be compensated through this picture. However it does give the bears something to throw around. Was she a paid shill?
|
|
|
|
Post by mnholdem on Jul 2, 2015 11:56:14 GMT -5
Let the bears go ahead whine (even post) about it... in the end they'll just wind up directing people to view the ad.  |
|
|
|
Post by mnkdnut on Jul 2, 2015 12:28:36 GMT -5
mnkdnut, great first post. I'm curious, for context can you share a little about what your past experience is with DTC campaigns? I hope you will post more. Also, what are your thoughts as to how a company evaluates the decision whether or not to supplement print DTC with TV, and the timing of such. I think Sanofi will go to TV when they feel there's enough prescriber capacity out there to handle the traffic effectively, both in terms of quantity and quality. Right now, there's probably too few that feel comfortable with all aspects of starting a patient on Afrezza. This will change (pedal to the metal on the peer-to-peer education!). Targeting Diabetes publications generates a higher quality of prospective patients - which should make the prescribers job easier. Consider the process they will go through in clearing insurance coverage and figuring out the right dosing (monitoring their BGs while they figure out how many units and when best to take them). You want motivated and qualified prospects. TV will generate more prospective patients, including a lot more unqualified prospects. The annoyance factor could be high if they start TV too soon. In my experience, heavy DTC that is too broad and/or too early will generate both ends of the prescriber spectrum: those doctors that are thrilled to get more patients who are excited about the new therapy, and those that are furious because they are unwilling or unprepared to handle the new traffic. If you're a small/medium sized one-product company, maybe you tolerate the latter to get enough of the former, but if you are Sanofi, I think you need to minimize the latter. That being said, I think it's absolutely essential to have the massive distribution power of a company like Sanofi. We just have to be patient while they build a proper foundation to grow from. Afrezza: too good to fail. |
|
|
|
Post by mnkdd on Jul 2, 2015 12:47:42 GMT -5
|
|
